Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Large ASCERT Observational Study Favors CABG Over PCI

This article was originally published in The Gray Sheet

Executive Summary

Bypass graft surgery had a relative risk reduction of about 20% long term compared to stenting.

You may also be interested in...

FREEDOM Trial’s Data Favors CABG Over PCI For Patients With Diabetes

Patients in the trial showed significantly reduced rates in the composite outcome of death, heart attacks and strokes after five years with CABG versus percutaneous coronary intervention.

Research In Brief

Data from annual gatherings of the Society of Thoracic Surgeons and the American Stroke Association, and more.

CABG Beats DES In SYNTAX Trial; Observers Expect Little Change In Practice

Analysts and physicians predict one-year results from the SYNTAX trial will have little short-term impact on demand for drug-eluting stents, even though the devices performed worse than coronary artery bypass graft (CABG) surgery in this seminal randomized trial





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts